-
公开(公告)号：US20200165582A1
公开(公告)日：2020-05-28
申请号：US16704744
申请日：2019-12-05
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G.K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
公开(公告)号：US20200164056A1
公开(公告)日：2020-05-28
申请号：US16704701
申请日：2019-12-05
Applicant: PFIZER INC.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Judith Absalon , Jose Miguel Aste-Amezaga , Johannes Frederik Beeslaar , David Cooper , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Isis Kanevsky , Lakshmi Khandke , Paul Liberator , John Lance Perez , Lynn Marie Phelan , Gary Warren Zlotnick
IPC: A61K39/095 , A61P31/00 , A61K47/64 , A61K31/7028 , A61K47/26 , A61K47/10 , A61K47/18 , C07K16/12 , C07K14/22 , A61K39/12
Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
-
公开(公告)号：US20190231861A1
公开(公告)日：2019-08-01
申请号：US16196150
申请日：2018-11-20
Applicant: PFIZER INC.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Judith Absalon , Jose Miguel Aste-Amezaga , Johannes Frederik Beeslaar , David Cooper , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Isis Kanevsky , Lakshmi Khandke , Paul Liberator , John Lance Perez , Lynn Marie Phelan , Gary Warren Zlotnick
IPC: A61K39/095 , A61K31/7028 , C07K14/22 , A61K47/26 , A61K47/64 , A61K47/18 , C07K16/12 , A61P31/00 , A61K47/10
Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
-
Patent Agency Ranking
公开(公告)号：US20190112584A1
公开(公告)日：2019-04-18
申请号：US16104938
申请日：2018-08-19
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
公开(公告)号：US20180214532A1
公开(公告)日：2018-08-02
申请号：US15883334
申请日：2018-01-30
Applicant: PFIZER INC.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Judith Absalon , Jose Miguel Aste-Amezaga , Johannes Frederik Beeslaar , David Cooper , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Isis Kanevsky , Lakshmi Khandke , Paul Liberator , John Lance Perez , Lynn Marie Phelan , Gary Warren Zlotnick
IPC: A61K39/095 , C07K14/22 , C07K16/12 , A61K31/7028 , A61K47/10 , A61K47/26 , A61K47/18
CPC classification number: A61K39/095 , A61K31/7028 , A61K47/10 , A61K47/183 , A61K47/26 , A61K47/6415 , A61K47/646 , A61P31/00 , C07K14/22 , C07K16/1217
Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
-
公开(公告)号：US20180000923A1
公开(公告)日：2018-01-04
申请号：US15543232
申请日：2016-02-16
Applicant: Pfizer Inc.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US09802987B2
公开(公告)日：2017-10-31
申请号：US14773324
申请日：2014-03-05
Applicant: PFIZER INC.
Inventor： Deborah Ann Dilts , Annaliesa Sybil Anderson , Kathrin Ute Jansen , Justin Keith Moran , Mark E Ruppen , Eugene Joseph Vidunas
IPC: A61K39/00 , A61K39/02 , A61K39/38 , A61K39/385 , C07K14/22 , A61K39/095 , C07K14/315 , A61K39/09
CPC classification number: C07K14/22 , A61K39/092 , A61K39/095 , A61K2039/6037 , A61K2039/6068 , C07K14/3156 , C07K2319/00 , C07K2319/55
Abstract: In one aspect, the invention relates to an isolated polypeptide including the amino acid sequence of a carrier polypeptide and the amino acid sequence of an ORF2086 polypeptide. In another aspect, the invention relates to an immunogenic conjugate including ORF2086 polypeptide and a carrier polypeptide. The invention further includes immunogenic compositions and methods for inducing an immune response against Neisseria meningitidis in a mammal.
-
公开(公告)号：US09561269B2
公开(公告)日：2017-02-07
申请号：US14604620
申请日：2015-01-23
Applicant: PFIZER INC.
Inventor： Gary Warren Zlotnick , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark E. Ruppen , Annaliesa Sybil Anderson , John Erwin Farley , Liesel A. Bernfield
IPC: A61K39/095 , C07K16/22 , C07K14/22 , C07K16/12 , A61K39/00
CPC classification number: A61K39/095 , A61K2039/55577 , A61K2039/6018 , C07K14/22 , C07K16/1217
Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
Abstract translation: 一方面，本发明涉及包含与SEQ ID NO：71具有至少95％同一性的氨基酸序列的分离多肽。另一方面，本发明涉及免疫原性组合物，其包含分离的非脂化非 - 来自脑膜炎奈瑟氏球菌血清群B的丙酮酸化ORF2086多肽和来自脑膜炎球菌血清群的至少一种共轭荚膜糖。
-
-
-
-
-
-
-
Search Results
78
records
(took 0.037 seconds)
